Prolific Machines
Series C
Prolific Machines develops a light-controlled platform that programs living cells to manufacture therapeutic proteins and other bioproducts.
Prolific Machines develops a light-controlled platform that programs living cells to manufacture therapeutic proteins and other bioproducts.
Prolific Machines operates in a category it created, commercial molecular optogenetics for biomanufacturing, and is the first company to integrate light-controlled cell line development at production scale. Public web sources surface no direct commercial rival offering a comparable light-based cell manufacturing platform.
The adjacent market is incumbent chemically induced expression systems and contract development and manufacturing organizations. Those incumbents are largely Prolific Machines' customers and partners rather than competitors, with nine of the top ten contract manufacturers and seven of the top ten biopharma companies having engaged the firm, and the Gates Foundation is a paying customer.
The Photomolecular platform is Prolific Machines' next-generation cell line development system for biotherapeutics, using light instead of chemical inducers to control how mammalian cells express proteins.
It pairs optogenetic host cell lines with illumination hardware that fits any existing bioreactor and AI-driven bioprocess optimization that adjusts light in real time, applying the same light-mediated control across transcription, the secretory pathway, and post-translational modification.
Prolific Machines sells preclinical cell line and process development services alongside platform licensing to biotechs, pharmaceutical companies, and contract manufacturers, positioning light-controlled manufacturing as a faster, lower-cost alternative to incumbent expression systems.
After setting a new antibody productivity benchmark, nine of the top ten contract manufacturers and seven of the top ten biopharma companies engaged Prolific Machines, the company is fully booked, and the Gates Foundation is a paying customer.
Light is cheap, instant, and digital, so the same software that controls a cell line can drive biology in real time rather than relying on the slow, expensive chemical induction the industry has used for decades.
In May 2026 Prolific Machines reported a 21 g/L antibody titer that doubled standard fed-batch performance through light-controlled gene expression, and the platform has produced up to 5.6-fold higher monoclonal antibody titer against CMV controls.
In April 2025 Prolific Machines completed an optogenetic bioproduction run at the 200 liter scale, which it called the largest optogenetics demonstration to date. That milestone indicates the platform is still being scaled toward full commercial manufacturing volumes.
Because the approach is a novel modality rather than an established chemically induced process, bioreactor operators must adopt new illumination hardware and optogenetic cell lines alongside their existing equipment. Incumbent contract development and manufacturing organizations already run proven expression systems at established commercial scales.
